NASDAQ:KLDO Kaleido Biosciences (KLDO) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 10:37 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitors About Kaleido Biosciences Stock (NASDAQ:KLDO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kaleido Biosciences alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.00▼$0.20Volume14,742 shsAverage Volume2,233 shsMarket Capitalization$4.26 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Kaleido Biosciences, Inc. was a clinical-stage biotechnology company focused on developing microbiome metabolic therapies (MMTs). Its approach used engineered, non-systemic glycans intended to selectively nourish beneficial bacteria in the human microbiome and encourage the production of metabolites that could influence disease-related biological processes. The company’s development pipeline included KB109, an investigational synthetic glycan evaluated in gastrointestinal and infectious-disease applications, including studies involving COVID-19 and respiratory infections. Kaleido also investigated other microbiome-targeted candidates, including KB174 for phenylketonuria and additional programs aimed at metabolic, inflammatory and immune-related conditions. Kaleido Biosciences was founded in 2015 and was based in the United States. In 2022, the company announced plans to wind down operations and discontinue its development programs. As a result, Kaleido is principally of historical interest as a biotechnology company that pursued a chemistry-based approach to microbiome therapeutics.AI Generated. May Contain Errors. Read More Receive KLDO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KLDO Stock News HeadlinesKaleido Biosciences Insider Trading Activity | OTC:KLDO | BenzingaApril 20, 2026 | benzinga.comKaleido Biosciences Inc.February 18, 2026 | marketwatch.comThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about what $375,000 did five years ago, even though no statement shows the change. Central banks have bought over 1,000 tonnes of gold a year for three straight years, using the same published data now explained in a free guide. The guide breaks down what's driving the shift in plain English, so readers can see the numbers for themselves.September 24 at 1:00 AM | American Alternative (Ad)Kaleido Biosciences Inc (KLDO)April 10, 2025 | uk.investing.comSyniverse Named Leader in Mobile Roaming by Kaleido Intelligence for Fourth Straight YearDecember 11, 2024 | finance.yahoo.comBICS, Cellusys, Comfone, Mobileum, Syniverse, Telefónica Global Solutions & TOMIA MACH Named Champion Roaming Vendors by Kaleido IntelligenceNovember 25, 2024 | markets.businessinsider.comKaleido Biosciences (OTC:KLDO) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comKaleido announces the appointment of RBC Investor Services as the new custodian of its scholarship plansOctober 1, 2024 | ca.finance.yahoo.comSee More Headlines KLDO Stock Analysis - Frequently Asked Questions How have KLDO shares performed this year? Kaleido Biosciences' stock was trading at $0.0001 at the beginning of the year. Since then, KLDO stock has increased by 0.0% and is now trading at $0.0001. How were Kaleido Biosciences' earnings last quarter? Kaleido Biosciences, Inc. (NASDAQ:KLDO) announced its earnings results on Monday, November, 1st. The company reported ($0.54) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.54). The business earned $0.10 million during the quarter, compared to the consensus estimate of $0.25 million. When did Kaleido Biosciences IPO? Kaleido Biosciences (KLDO) raised $101 million in an initial public offering on Thursday, February 28th 2019. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity was co-manager. How do I buy shares of Kaleido Biosciences? Shares of KLDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kaleido Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kaleido Biosciences investors own include Editas Medicine (EDIT), Enovix (ENVX), Compass Pathways (CMPS), Rambus (RMBS), Luminar Technologies (LAZR), Precision BioSciences (DTIL) and Globant (GLOB). Company Calendar Last Earnings11/01/2021Today9/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorTechnology Industry Software Sub-IndustryApplication Software Current SymbolNASDAQ:KLDO CIK1751299 Webwww.kaleido.com Phone(617) 674-9000FaxN/AEmployees76Year Founded2015Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.10 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares42,623,000Free Float38,787,000Market Cap$4.26 thousand OptionableNot Optionable Beta-0.06 Social Links 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:KLDO) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...Behind the Markets | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kaleido Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kaleido Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
